Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia

Nicole Kucine, Shayla Bergmann, Spencer Krichevsky, Devin Jones, Michael Rytting, Juhi Jain, Carolyn M. Bennett, Linda M.S. Resar, John Mascarenhas, Srdan Verstovsek, Ronald Hoffman

Research output: Contribution to journalArticlepeer-review


Myeloproliferative neoplasms (MPN) are rare disorders in young patients, and because of this, standardized treatment recommendations are not available. Pediatric patients are more frequently treated with hydroxyurea than interferon, yet there are no data suggesting this is the best practice. Current treatment guidelines for adults suggest using interferon as upfront therapy in young patients. We reviewed the cases of 13 young patients with polycythemia vera or essential thrombocythemia, who were treated with interferon. Extreme thrombocytosis was well controlled and the medication was tolerated by many. Our work shows the need for prospective studies evaluating interferon in our youngest patients with MPN.

Original languageEnglish (US)
Article numbere28888
JournalPediatric Blood and Cancer
Issue number3
StatePublished - Mar 2021


  • essential thrombocytosis
  • interferon
  • myeloproliferative neoplasm
  • polycythemia vera

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia'. Together they form a unique fingerprint.

Cite this